High incidence of proliferative and membranous nephritis in SLE patients with low proteinuria in the Accelerating Medicines Partnership.
Saved in:
| Title: | High incidence of proliferative and membranous nephritis in SLE patients with low proteinuria in the Accelerating Medicines Partnership. |
|---|---|
| Authors: | Carlucci PM; Department of Medicine, New York University School of Medicine, New York, NY., Li J; Division of Rheumatology, Department of Medicine, Johns Hopkins University, Baltimore, MD., Fava A; Division of Rheumatology, Department of Medicine, Johns Hopkins University, Baltimore, MD., Deonaraine KK; Department of Medicine, New York University School of Medicine, New York, NY., Wofsy D; Rheumatology Division, Department of Medicine, Russell/Engleman Rheumatology Research Center, University of California San Francisco, San Francisco, CA., James JA; Department of Medicine, Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK., Putterman C; Division of Rheumatology, Department of Microbiology and Immunology, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, NY, USA.; Azrieli Faculty of Medicine, Bar-Ilan University, Zefat, Israel., Diamond B; Institute of Molecular Medicine, Feinstein Institutes for Medical Research, Manhasset, NY., Davidson A; Institute of Molecular Medicine, Feinstein Institutes for Medical Research, Manhasset, NY., Fine DM; Division of Nephrology, Department of Medicine, Johns Hopkins University, Baltimore, MD., Monroy-Trujillo J; Division of Nephrology, Department of Medicine, Johns Hopkins University, Baltimore, MD., Atta MG; Division of Nephrology, Department of Medicine, Johns Hopkins University, Baltimore, MD., DeJager W; Department of Medicine, Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK., Guthridge JM; Department of Medicine, Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK., Haag K; Division of Rheumatology, Department of Medicine, Johns Hopkins University, Baltimore, MD., Rao DA; Division of Rheumatology, Inflammation, Immunity, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA., Brenner MB; Division of Rheumatology, Inflammation, Immunity, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA., Lederer JA; Division of Rheumatology, Inflammation, Immunity, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA., Apruzzese W; Division of Rheumatology, Inflammation, Immunity, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA., Belmont HM; Department of Medicine, New York University School of Medicine, New York, NY., Izmirly PM; Department of Medicine, New York University School of Medicine, New York, NY., Zaminski D; Department of Medicine, New York University School of Medicine, New York, NY., Wu M; Department of Medicine, New York University School of Medicine, New York, NY., Connery S; Department of Internal Medicine, Paul L. Foster School of Medicine, Texas Tech University Health Sciences Center El Paso, El Paso, TX., Payan-Schober F; Department of Internal Medicine, Paul L. Foster School of Medicine, Texas Tech University Health Sciences Center El Paso, El Paso, TX., Furie R; Division of Rheumatology, Department of Medicine, Northwell Health, Great Neck, NY., Dall'Era M; Rheumatology Division, Department of Medicine, Russell/Engleman Rheumatology Research Center, University of California San Francisco, San Francisco, CA., Cho K; Nephrology Division, Department of Medicine, University of California San Francisco, San Francisco, CA., Kamen D; Division of Rheumatology and Immunology, Department of Medicine, Medical University of South Carolina, Charleston, SC., Kalunian K; Department of Medicine, University of California San Diego School of Medicine, La Jolla, CA., Anolik J; Department of Medicine, Division of Allergy, Immunology, and Rheumatology, University of Rochester Medical Center, Rochester, NY., Barnas J; Department of Medicine, Division of Allergy, Immunology, and Rheumatology, University of Rochester Medical Center, Rochester, NY., Ishimori M; Division of Rheumatology, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA., Weisman MH; Division of Rheumatology, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA., Buyon JP; Department of Medicine, New York University School of Medicine, New York, NY., Petri M; Division of Rheumatology, Department of Medicine, Johns Hopkins University, Baltimore, MD. |
| Corporate Authors: | Accelerating Medicines Partnership (AMP) RA/SLE Network |
| Source: | Rheumatology (Oxford, England) [Rheumatology (Oxford)] 2022 Nov 02; Vol. 61 (11), pp. 4335-4343. |
| Publication Type: | Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural |
| Journal Info: | Publisher: Oxford University Press Country of Publication: England NLM ID: 100883501 Publication Model: Print Cited Medium: Internet ISSN: 1462-0332 (Electronic) Linking ISSN: 14620324 NLM ISO Abbreviation: Rheumatology (Oxford) Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
